1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Jilin Aodong Pharmaceutical Group Co., Ltd.

Jilin Aodong Pharmaceutical Group Co., Ltd.

000623.SZ
Jilin Aodong Pharmaceutical Group Co., Ltd.CN flagShenzhen Stock Exchange
18.06
CNY
-0.70
- -
21.60BMarket Cap
Jilin Aodong Pharmaceutical Group Co., Ltd.
000623.SZ
(Shenzhen Stock Exchange)

Recent

price

18.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.96
0.99
1.24
1.68
1.93
2.01
2.38
2.56
2.86
2.66
1.94
2.02
2.53
3.06
2.22
1.99
1.98
Revenue per Share
1.07
1.71
0.55
0.91
1.22
2.23
1.45
1.6
0.8
1.21
1.48
1.56
1.57
1.3
1.32
2.04
1.95
Basic EPS, GAAP
0.02
-0.3
-0.05
-0.09
-0.1
0.05
0.15
0.15
0.09
0.14
0.14
0.01
0.13
-0.31
-0.18
0.12
-0.13
Free Cash Flow per Basic Share
0.09
0.01
0.12
0.08
0.08
0.17
0.26
0.23
0.3
0.21
0.22
0.22
0.33
0.36
0.9
0.55
0.87
Dividend per Share
5.27
6.97
7.36
6.97
8.05
9.81
11.04
12.24
12.51
13.42
14.58
16
17.23
18.26
17.82
19.21
18.64
Book Value per Share
6.06
7.64
8.12
9.29
10.65
14.8
16.12
17.36
17.89
18.96
19.93
21.51
22.72
23.91
24.41
25.95
25.24
Tangible Book Value per Share
1,162
1,161
1,167
1,166
1,161
1,163
1,149
1,163
1,163
1,163
1,158
1,139
1,135
1,125
1,177
1,173
1,176
Basic Weighted Avg Shares
1,113
1,145
1,445
1,957
2,240
2,335
2,737
2,977
3,324
3,088
2,252
2,304
2,868
3,449
2,611
2,335
2,325
Sales/Revenue/Turnover
11.06
11.3
9.45
11.13
14.29
13.14
14.13
14.79
12.33
9.59
2.37
4.89
8.38
7.74
-2.65
-2.69
-3.76
Operating Margin (%)
73
71
83
95
107
135
161
179
187
194
195
204
226
234
235
215
- -
Depreciation Expense
1,238
1,982
646
1,059
1,411
2,594
1,666
1,863
935
1,404
1,709
1,781
1,781
1,460
1,551
2,395
2,295
Net Income, GAAP
2.64
19.45
4.79
10.8
4.54
2.56
4.84
4.55
6.5
5.84
1.46
- -
- -
3.72
0.15
2.45
4.53
Effective Tax Rate (%)
111.17
173.07
44.72
54.11
62.97
111.09
60.89
62.6
28.13
45.45
75.89
77.29
62.09
42.33
59.43
102.57
98.72
Profit Margin (%)
1,175
1,308
1,450
1,895
2,178
1,282
2,157
2,107
5,143
5,322
4,782
4,870
3,767
1,277
2,369
2,809
2,664
Working Capital
19
23
- -
- -
22
22
- -
- -
1,910
2,006
2,144
2,235
2,321
21
1,012
1,303
1,094
LT Debt
7,246
9,095
9,753
11,100
12,659
17,584
18,874
20,514
21,244
22,445
23,529
25,039
26,338
27,500
29,282
30,887
30,212
Total Equity
1.74
1.28
1.38
1.86
2.56
1.91
1.95
2.12
1.75
1.17
0.21
- -
- -
0.86
-0.22
-0.19
-0.26
Return on Invested Capital (%)
20.95
27.5
7.63
12.5
15.89
23.57
13.26
13.69
6.58
8.77
9.88
- -
- -
6.91
7.07
10.22
9.99
Return on Capital (%)
22.04
27.9
7.75
12.66
16.15
25
13.83
13.85
6.5
9.31
10.52
10.14
9.42
7.28
7.47
11.01
10.85
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,277
1,367
1,168
LT Borrowings
995
996
1,086
LT Finance Leases
17
15
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,196
1,196
1,196
Market Capitalization
19,429
19,352
19,928

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
4,833
4,831
5,275
Cash, Cash Equivalents & STI
2,675
2,650
3,202
Accounts Receivable, Net
787
933
788
Inventories
937
893
891
Total Current Liabilities
2,464
2,582
2,611
Payables & Accruals
- -
- -
- -
ST Debt
1,277
1,367
1,168
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.81%
5.6%
5.48%
Free Cash Flow
83.62%
119.1%
-167.04%
Net Income, GAAP
4.49%
9.37%
54.39%
Sales/Revenue/Turnover
1.57%
2.44%
-10.55%
Total Cash Common Dividend
22.35%
36.19%
-38.77%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
861
550
498
701
2,611
2025
623
504
695
- -
2,335
2026
514
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
- -
- -
- -
1.32
2025
0.44
- -
- -
- -
2.04
2026
0.74
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
- -
- -
- -
0.9
2025
0.01
- -
- -
- -
0.55
2026
0.01
- -
- -
- -
- -
Similar Companies
Gufic Biosciences Limited (GUFICBIO.NS)
Toleranzia AB (TOL.ST)
Huons Global Co., Ltd. (084110.KQ)
Animalcare Group plc (ANCR.L)
High Tide Inc. (HITTF)
Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ)
Business
Jilin Aodong Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products with a strong focus on traditional Chinese medicine (TCM) and Western pharmaceuticals. The company's main products include prescription medications, over-the-counter drugs, oral liquid solutions, injections, capsules, granules, tablets, Chinese herbal medicines, powders, tonic medicines, enzymes, biochemical medicines, and plant chemical medicines. Key branded products include Calming the Brain Solution, Pediatric Chai Gui Antipyretic Oral Solution, Blood Enhancing Drink Oral Liquid, Ribonucleic Acid for Injection, Pingyangmycin Hydrochloride for Injection, Astragalus Hypoglycemic Capsules, Adenosylmethionine Butanedisulfonate for Injection, Muscle Extender Tablets, and Jinlianhua Oral Liquid, among others. The company also produces pharmaceutical excipients, packaging materials, enzyme stock solutions, ginseng and antler products, health care products, and processes edible agricultural products. Its product range covers therapeutic areas such as cardiovascular, women and children medication, liver, gallbladder, and stomach care, antipyretic and analgesic, rheumatic bone disease, antibacterial and anti-inflammatory, cough and phlegm relief, and urinary medication. Beyond pharmaceuticals, the company operates in related sectors including highway construction and toll collection, animal husbandry, specialty chemicals manufacturing, and utility services such as heat and water supply. Founded in 1957, Jilin Aodong is headquartered in Dunhua, Jilin Province, China, and exports products to over 20 countries including the United States, Canada, and Southeast Asia. Recent major company changes include a continued strategic emphasis on digital transformation and innovation in drug development, with investments in telemedicine and artificial intelligence technologies to address modern healthcare challenges. In 2022, Jilin Aodong launched 10 new products primarily targeting respiratory and digestive health. The company has also expanded its international footprint and diversified its business portfolio to stabilize revenue streams amid industry volatility. It has maintained a stable return on equity around 15.2% over recent years and demonstrated strong liquidity positioning. Jilin Aodong continues to pursue international collaborations and innovative R&D initiatives while sustaining its commitment to integrating traditional practices with modern scientific approaches to enhance efficacy and safety in pharmaceutical products. The executive and management teams consist of experienced industry veterans who retain significant control over strategic direction. This comprehensive approach positions Jilin Aodong as a leading pharmaceutical and healthcare company in China with growing global ambitions.